OA12774A - Controlled synthesis of ziprasidone and compositions thereof. - Google Patents

Controlled synthesis of ziprasidone and compositions thereof. Download PDF

Info

Publication number: OA12774A
Authority: OA; OAPI
Prior art keywords: composition; dihydro; indol; ziprasidone; chloro
Prior art date: 2002-02-20

Application number

OA1200400216A

Other languages

English (en)

Inventor

Frank Robert Busch

Adam Worth Grobin

Howard Harry Ralph Jr

Kyle Robert Leeman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-20

Filing date

2003-02-17

Publication date

2006-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12774(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-17 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-07-04 Publication of OA12774A publication Critical patent/OA12774A/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Liquid Crystal Substances (AREA)
Indole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pyridine Compounds (AREA)

OA1200400216A 2002-02-20 2003-02-17 Controlled synthesis of ziprasidone and compositions thereof. OA12774A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US35880602P	2002-02-20	2002-02-20
US35903802P	2002-02-21	2002-02-21
US36045902P	2002-02-27	2002-02-27

Publications (1)

Publication Number	Publication Date
OA12774A true OA12774A (en)	2006-07-04

Family

ID=27761437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400216A OA12774A (en)	2002-02-20	2003-02-17	Controlled synthesis of ziprasidone and compositions thereof.

Country Status (41)

Country	Link
EP (1)	EP1476162B1 (pl)
JP (1)	JP4554938B2 (pl)
KR (1)	KR100773622B1 (pl)
CN (2)	CN101735212A (pl)
AP (1)	AP2004003103A0 (pl)
AR (1)	AR038563A1 (pl)
AT (1)	ATE359787T1 (pl)
AU (2)	AU2003206035A1 (pl)
BR (1)	BR0307833A (pl)
CA (1)	CA2475302C (pl)
CO (1)	CO5611138A2 (pl)
CY (1)	CY1106467T1 (pl)
DE (1)	DE60313289T2 (pl)
DK (1)	DK1476162T3 (pl)
EA (1)	EA007866B1 (pl)
EC (1)	ECSP045239A (pl)
ES (1)	ES2283745T3 (pl)
GE (1)	GEP20074030B (pl)
GT (1)	GT200300040A (pl)
HR (1)	HRP20040711A2 (pl)
IL (1)	IL163277A (pl)
IS (1)	IS7344A (pl)
MA (1)	MA27177A1 (pl)
MX (1)	MXPA04006993A (pl)
MY (1)	MY139523A (pl)
NO (2)	NO20043902L (pl)
NZ (1)	NZ534443A (pl)
OA (1)	OA12774A (pl)
PA (1)	PA8567001A1 (pl)
PE (1)	PE20030942A1 (pl)
PL (1)	PL372238A1 (pl)
PT (1)	PT1476162E (pl)
RS (1)	RS60404A (pl)
SI (1)	SI1476162T1 (pl)
SV (1)	SV2004001485A (pl)
TN (1)	TNSN04159A1 (pl)
TW (1)	TW200307546A (pl)
UA (1)	UA77057C2 (pl)
UY (1)	UY27668A1 (pl)
WO (1)	WO2003070246A1 (pl)
ZA (1)	ZA200406276B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1263729B1 (en)	2000-03-06	2006-12-20	Acadia Pharmaceuticals Inc.	Azacyclic compounds for use in the treatment of serotonin related diseases
KR100974901B1 (ko)	2001-12-28	2010-08-10	아카디아 파마슈티칼스 인코포레이티드	모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7538222B2 (en)	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en)	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko)	2002-06-24	2005-01-21	아카디아 파마슈티칼스 인코포레이티드	세로토닌 수용체 제제로서의 ｎ-치환된 피페리딘 유도체
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en)	2002-12-04	2009-02-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
CA2512639C (en)	2003-01-16	2012-10-30	Acadia Pharmaceuticals Inc.	Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
EP1511739B1 (en)	2003-03-17	2008-04-30	Teva Pharmaceutical Industries Ltd.	Polymorphs of valsartan
US7199144B2 (en)	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
US7378531B2 (en)	2003-04-21	2008-05-27	Teva Pharmaceutical Industries Ltd	Process for the preparation of valsartan
EP1546146A1 (en)	2003-06-03	2005-06-29	Teva Pharmaceutical Industries Limited	POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
CA2543805A1 (en)	2003-10-24	2005-05-06	Gideon Pilarsky	Processes for preparation of ziprasidone
CA2550485A1 (en) *	2003-12-18	2005-07-07	Teva Pharmaceutical Industries Ltd.	Polymorphic form b2 of ziprasidone base
ES2334800T3 (es)	2004-02-27	2010-03-16	Ranbaxy Laboratories Limited	Proceso para la preparacion de ziprasidona.
CA2467538C (en)	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en)	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en)	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
KR101260036B1 (ko)	2004-09-27	2013-05-06	아카디아 파마슈티칼스 인코포레이티드	Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2250001B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Procedimiento para la preparacion de ziprasidona.
EP1841764A1 (en) *	2005-01-27	2007-10-10	Hetero Drugs Limited	Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) *	2005-11-18	2007-05-19	Dipharma Spa	Procedimento per la preparazione di ziprasidone
CN100491375C (zh) *	2006-07-01	2009-05-27	浙江美诺华药物化学有限公司	一种齐拉西酮的制备方法
ES2423485T3 (es)	2007-03-19	2013-09-20	Acadia Pharmaceuticals Inc.	Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
CN102234273B (zh) *	2010-04-21	2015-08-05	上海医药工业研究院	甲磺酸齐拉西酮半水合物及其制备方法
CN102234272A (zh) *	2010-04-21	2011-11-09	上海医药工业研究院	盐酸齐拉西酮半水合物的制备方法
EP3325444B1 (en)	2015-07-20	2021-07-07	Acadia Pharmaceuticals Inc.	Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017165635A1 (en)	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en)	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en)	2016-12-20	2019-10-30	Acadia Pharmaceuticals Inc.	Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) *	2016-12-26	2018-07-03	四川科瑞德凯华制药有限公司	一种甲磺酸齐拉西酮的纯化及制备方法
US11135211B2 (en)	2017-04-28	2021-10-05	Acadia Pharmaceuticals Inc.	Pimavanserin for treating impulse control disorder
WO2019046167A1 (en)	2017-08-30	2019-03-07	Acadia Pharmaceuticals Inc.	PIMAVANSERIN FORMULATIONS
CN112724066B (zh) *	2021-02-04	2022-10-21	海南鑫开源医药科技有限公司	一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) *	2023-01-17	2023-05-02	北京协和建昊医药技术开发有限责任公司	一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) *	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
KR100315939B1 (ko)	1995-11-07	2002-01-16	디. 제이. 우드, 스피겔 알렌 제이	3-(1-피페라지닐)-1,2-벤즈이소티아졸의제조방법및중간체
IL126590A (en) *	1996-05-07	2001-11-25	Pfizer	Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it
TW491847B (en) *	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations

2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 PL PL03372238A patent/PL372238A1/pl not_active Application Discontinuation
- 2003-02-17 CA CA002475302A patent/CA2475302C/en not_active Expired - Fee Related
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active Expired - Fee Related
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-17 EP EP03702918A patent/EP1476162B1/en not_active Revoked
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/en not_active Ceased
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP4554938B2 (ja)	2010-09-29
IL163277A (en)	2010-05-31
PE20030942A1 (es)	2003-11-08
UA77057C2 (en)	2006-10-16
CA2475302C (en)	2009-05-12
PA8567001A1 (es)	2003-12-10
CN101735212A (zh)	2010-06-16
IS7344A (is)	2004-07-05
EA007866B1 (ru)	2007-02-27
TNSN04159A1 (fr)	2007-03-12
TW200307546A (en)	2003-12-16
KR20040086417A (ko)	2004-10-08
WO2003070246A1 (en)	2003-08-28
JP2005525347A (ja)	2005-08-25
RS60404A (sr)	2006-10-27
CY1106467T1 (el)	2012-01-25
NO20043902L (no)	2004-09-17
CO5611138A2 (es)	2006-02-28
UY27668A1 (es)	2003-10-31
MA27177A1 (fr)	2005-01-03
DE60313289T2 (de)	2007-12-27
GT200300040A (es)	2007-01-12
CA2475302A1 (en)	2003-08-28
ZA200406276B (en)	2005-09-20
AU2009202008A1 (en)	2009-06-11
AR038563A1 (es)	2005-01-19
BR0307833A (pt)	2004-12-07
SV2004001485A (es)	2004-05-07
MY139523A (en)	2009-10-30
PL372238A1 (pl)	2005-07-11
NZ534443A (en)	2007-07-27
KR100773622B1 (ko)	2007-11-05
ATE359787T1 (de)	2007-05-15
EP1476162A1 (en)	2004-11-17
ES2283745T3 (es)	2007-11-01
EA200400815A1 (ru)	2004-12-30
GEP20074030B (en)	2007-02-12
CN1635892A (zh)	2005-07-06
MXPA04006993A (es)	2004-11-10
DE60313289D1 (de)	2007-05-31
ECSP045239A (es)	2004-09-28
PT1476162E (pt)	2007-06-25
HRP20040711A2 (en)	2004-12-31
DK1476162T3 (da)	2007-07-02
AP2004003103A0 (en)	2004-09-30
SI1476162T1 (sl)	2007-08-31
AU2003206035A1 (en)	2003-09-09
EP1476162B1 (en)	2007-04-18
NO20100584L (no)	2004-09-17

Publication	Publication Date	Title
CA2475302C (en)	2009-05-12	Controlled synthesis of ziprasidone and compositions thereof
US5021421A (en)	1991-06-04	2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
DE69918278T2 (de)	2005-07-14	Substituierte indolalkansäure
DE69916881T2 (de)	2005-02-03	Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure
US20040048876A1 (en)	2004-03-11	Ziprasidone composition and synthetic controls
JP2020503298A (ja)	2020-01-30	単環式ｏｇａ阻害剤化合物
KR19990066852A (ko)	1999-08-16	정신병 증상의 치료방법
CN103228643B (zh)	2015-11-25	作为组胺h4受体配体的苯并唑衍生物
JP2002536291A (ja)	2002-10-29	２−（４−アリール又はヘテロアリール−ピペラジン−１−イルメチル）−１ｈ−インドール誘導体
HUT70518A (en)	1995-10-30	New indol derivatives, pharmaceutical compositions containing them and process for producing them
MXPA06001229A (es)	2006-05-15	Derivados de 1-sulfonilindol, su preparacion y su uso como ligandos de 5-ht6.
EP4125910B1 (en)	2025-11-12	Rho kinase inhibitors for treating frontotemporal dementia
JPH11508280A (ja)	1999-07-21	三環式アミノアルキルカルボキサミド；新規なドーパミンｄ▲下３▼受容体サブタイプに特異的なリガンド
CN1355800A (zh)	2002-06-26	噻唑烷二酮衍生物及其作为抗糖尿病药的用途
WO2004046134A2 (en)	2004-06-03	Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
KR100621249B1 (ko)	2006-10-24	투렛증후군을치료하기위한약학조성물
AU2019289968A1 (en)	2020-12-17	OGA inhibitor compounds
JP4557112B2 (ja)	2010-10-06	ベンゾオキサゾール誘導体及び該誘導体を有効成分として含む医薬
KR20080046205A (ko)	2008-05-26	프로드럭으로서 피페라진 및 피페리딘 유도체의 ｎ-산화물
IL293929A (en)	2022-08-01	Oga inhibitor compounds
PL201176B1 (pl)	2009-03-31	Metanosulfonian 8-{4-[3-(5-fluoro-1H-indol-3-ilo)-propylo]-piperazyno-1-ylo}-2-metylo-4H-benzo[1,4]ksazyn-3-onu o powinowactwie do receptora dopaminy D2 i miejsca ponownego wychwytu serotoniny oraz kompozycja farmaceutyczna
SK51052006A3 (sk)	2007-05-03	Pyridínové deriváty alkyloxindolov ako aktívne látky voči 5-HT7 receptoru
WO2025233532A1 (en)	2025-11-13	Maxi-k potassium channel openers and therapeutic applications thereof
KR20240006657A (ko)	2024-01-15	염색체 2, 2:107,510,000-107,540,000 유전자좌에서 단일 뉴클레오티드 다형성을 갖는 대상체를 진단 및 치료하는 방법
JPS63165368A (ja)	1988-07-08	新規複素環化合物およびその製造法